Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STELLAR III: Optimized immunotherapy plus neoadjuvant chemoradiotherapy for locally advanced rectal cancer
ChiCTR2500109612Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of capecitabine and oxaliplatin in rectal adenocarcinoma (4 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: CR rate. Started Sep 2025; status: recruiting.
02
Drugs
capecitabineoxaliplatin
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500109612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109612.